FOLFOXIRI/Bevacizumab Versus FOLFIRI/Bevacizumab as First-Line Treatment in Unresectable Metastatic Colorectal Cancer: Results of Phase III Tribe Trial by Gono Group-Reference-Cited by-同舟云学术

FOLFOXIRI/Bevacizumab Versus FOLFIRI/Bevacizumab as First-Line Treatment in Unresectable Metastatic Colorectal Cancer: Results of Phase III Tribe Trial by Gono Group

Published:2013-06 Issue: Volume:24 Page:iv21
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Cremolini Chiara,Loupakis Fotios,Masi Gianluca,Lonardi Sara,Zagonel Vittorina,Salvatore Lisa,Trenta Patrizia,Tomasello Gianluca,Ronzoni Monica,Ciuffreda Libero,Zaniboni Alberto,Tonini Giuseppe,Buonadonna Angela,Barbara Cecilia,Negri Francesca V.,Barone Carlo,Vitello Stefano,Giuntini Nicola,Bonetti Andrea,D'Amico Mauro,Boni Luca,Falcone Alfredo

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/24/suppl_4/iv21/6675962/mdt201.26.pdf

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systematic literature review and network meta-analysis of pembrolizumab versus other interventions for previously untreated, unresectable or metastatic, MSI-high or MMR-deficient CRC;Future Oncology;2022-06

2. Anti-angiogenic Treatment in Metastatic Colorectal Cancer: Current Issues and Future Aims;Current Cancer Therapy Reviews;2019-11-16

3. Predictive biomarkers candidates for patients with metastatic colorectal cancer treated with bevacizumab-containing regimen;Drug Metabolism and Personalized Therapy;2016-01-01

4. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Annals of Oncology;2014-09

5. A perspective on the current management of advanced colorectal cancer;Future Oncology;2013-11